EP1769791A3 - Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer - Google Patents

Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
EP1769791A3
EP1769791A3 EP06025392A EP06025392A EP1769791A3 EP 1769791 A3 EP1769791 A3 EP 1769791A3 EP 06025392 A EP06025392 A EP 06025392A EP 06025392 A EP06025392 A EP 06025392A EP 1769791 A3 EP1769791 A3 EP 1769791A3
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
treatment
cell cycle
cycle inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06025392A
Other languages
German (de)
English (en)
Other versions
EP1769791A2 (fr
EP1769791B1 (fr
Inventor
Zsuzsanna Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to EP10176680A priority Critical patent/EP2292238A1/fr
Priority to EP10176681A priority patent/EP2286803A1/fr
Priority to EP10176686A priority patent/EP2289511A1/fr
Priority to EP10176688A priority patent/EP2286875A1/fr
Priority to EP10176675A priority patent/EP2292240A1/fr
Publication of EP1769791A2 publication Critical patent/EP1769791A2/fr
Publication of EP1769791A3 publication Critical patent/EP1769791A3/fr
Application granted granted Critical
Publication of EP1769791B1 publication Critical patent/EP1769791B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
EP06025392A 2001-07-19 2002-07-19 Utilisation de dexrazoxane pour la prevention et le traitement de la maladie d'alzheimer Expired - Lifetime EP1769791B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10176680A EP2292238A1 (fr) 2001-07-19 2002-07-19 Utilisation des Steroides ou des glucocorticoides pour le traitement et la prevention de la maladie de Alzheimer
EP10176681A EP2286803A1 (fr) 2001-07-19 2002-07-19 Utilisation des antagonistes des alpha 1 adrénergic récepteurs pour la prévention et le traitement de la maladie d'Alzheimer
EP10176686A EP2289511A1 (fr) 2001-07-19 2002-07-19 Utilisation de rétinoïdes pour le traitement ou la prévention de la maladie d'Alzheimer
EP10176688A EP2286875A1 (fr) 2001-07-19 2002-07-19 Utilisation des ansamycines pour la prevention et le traitement de la maladie d'alzheimer
EP10176675A EP2292240A1 (fr) 2001-07-19 2002-07-19 Utilisation de la rapamycine pour le traitement et la prevention de la maladie de Alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117645.2A GB0117645D0 (en) 2001-07-19 2001-07-19 Therapeutic stratergies for prevention and treatment of alzheimers disease
EP02749036A EP1408938A1 (fr) 2001-07-19 2002-07-19 Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP02749036A Division EP1408938A1 (fr) 2001-07-19 2002-07-19 Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
EP02749036.6 Division 2002-07-19

Publications (3)

Publication Number Publication Date
EP1769791A2 EP1769791A2 (fr) 2007-04-04
EP1769791A3 true EP1769791A3 (fr) 2007-07-11
EP1769791B1 EP1769791B1 (fr) 2010-09-15

Family

ID=9918826

Family Applications (9)

Application Number Title Priority Date Filing Date
EP10176680A Withdrawn EP2292238A1 (fr) 2001-07-19 2002-07-19 Utilisation des Steroides ou des glucocorticoides pour le traitement et la prevention de la maladie de Alzheimer
EP10176675A Withdrawn EP2292240A1 (fr) 2001-07-19 2002-07-19 Utilisation de la rapamycine pour le traitement et la prevention de la maladie de Alzheimer
EP10176688A Withdrawn EP2286875A1 (fr) 2001-07-19 2002-07-19 Utilisation des ansamycines pour la prevention et le traitement de la maladie d'alzheimer
EP06025393A Expired - Lifetime EP1767197B1 (fr) 2001-07-19 2002-07-19 Stratégies thérapeutiques pour la prévention et le traitement de la maladie d'alzheimer
EP06025392A Expired - Lifetime EP1769791B1 (fr) 2001-07-19 2002-07-19 Utilisation de dexrazoxane pour la prevention et le traitement de la maladie d'alzheimer
EP02749036A Ceased EP1408938A1 (fr) 2001-07-19 2002-07-19 Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
EP10176681A Withdrawn EP2286803A1 (fr) 2001-07-19 2002-07-19 Utilisation des antagonistes des alpha 1 adrénergic récepteurs pour la prévention et le traitement de la maladie d'Alzheimer
EP10176686A Withdrawn EP2289511A1 (fr) 2001-07-19 2002-07-19 Utilisation de rétinoïdes pour le traitement ou la prévention de la maladie d'Alzheimer
EP06025394A Expired - Lifetime EP1764092B1 (fr) 2001-07-19 2002-07-19 Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EP10176680A Withdrawn EP2292238A1 (fr) 2001-07-19 2002-07-19 Utilisation des Steroides ou des glucocorticoides pour le traitement et la prevention de la maladie de Alzheimer
EP10176675A Withdrawn EP2292240A1 (fr) 2001-07-19 2002-07-19 Utilisation de la rapamycine pour le traitement et la prevention de la maladie de Alzheimer
EP10176688A Withdrawn EP2286875A1 (fr) 2001-07-19 2002-07-19 Utilisation des ansamycines pour la prevention et le traitement de la maladie d'alzheimer
EP06025393A Expired - Lifetime EP1767197B1 (fr) 2001-07-19 2002-07-19 Stratégies thérapeutiques pour la prévention et le traitement de la maladie d'alzheimer

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP02749036A Ceased EP1408938A1 (fr) 2001-07-19 2002-07-19 Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
EP10176681A Withdrawn EP2286803A1 (fr) 2001-07-19 2002-07-19 Utilisation des antagonistes des alpha 1 adrénergic récepteurs pour la prévention et le traitement de la maladie d'Alzheimer
EP10176686A Withdrawn EP2289511A1 (fr) 2001-07-19 2002-07-19 Utilisation de rétinoïdes pour le traitement ou la prévention de la maladie d'Alzheimer
EP06025394A Expired - Lifetime EP1764092B1 (fr) 2001-07-19 2002-07-19 Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer

Country Status (7)

Country Link
US (2) US8343926B2 (fr)
EP (9) EP2292238A1 (fr)
AT (3) ATE524169T1 (fr)
DE (1) DE60237725D1 (fr)
ES (3) ES2373565T3 (fr)
GB (1) GB0117645D0 (fr)
WO (1) WO2003007925A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7097996B2 (en) * 2002-09-06 2006-08-29 New York University Methods of screening test compounds using GADD34L, an eIF2α-specific phosphatase subunit
JP2006502188A (ja) * 2002-09-17 2006-01-19 ニューヨーク ユニバーシティ 年齢関連記憶欠陥（ａａｍｉ）、中程度認識欠陥（ｍｃｉ）、および痴呆を細胞周期インヒビターで処置する方法
PT3424932T (pt) * 2005-02-16 2021-05-19 Anacor Pharmaceuticals Inc Boronoftalidas para utilização terapêutica
RU2008131324A (ru) * 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
ES2728455T3 (es) 2006-02-16 2019-10-24 Anacor Pharmaceuticals Inc Moléculas pequeñas que contienen boro como agentes antiinflamatorios
EP2035003A1 (fr) * 2006-06-08 2009-03-18 The Govt Of The USA, As Represented By The Secretary, Department Of Health And Human Services Procédé de réduction de l'agrégation ou hyperphosphorylation de peptide utilisant une bisdioxopipérazine
US8633179B2 (en) * 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR101672511B1 (ko) 2008-03-06 2016-11-03 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
WO2009140309A2 (fr) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
WO2010028005A1 (fr) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
EP2348863A4 (fr) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
WO2010045503A1 (fr) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu’agents antiprotozoaires
CN102256494A (zh) * 2008-12-17 2011-11-23 阿纳科制药公司 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
MX2012001156A (es) * 2009-07-28 2012-05-08 Anacor Pharmaceuticals Inc Moleculas que contienen boro trisustituidas.
WO2011019618A1 (fr) * 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore et utilisables en tant qu'agents antiprotozoaires
MX2012002031A (es) * 2009-08-19 2012-07-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011049971A1 (fr) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore comme agents antiprotozoaires
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011060199A1 (fr) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Petites molecules contenant du bore
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011116348A1 (fr) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Petites molécules borées en tant qu'agent anti-protozoaire
EP2613788B1 (fr) 2010-09-07 2017-06-21 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
GB201112246D0 (en) * 2011-07-15 2011-08-31 Univ Birmingham Diagnosis of alzheimer's disease
EP3967299A1 (fr) * 2011-11-13 2022-03-16 Cognitive Research Enterprises, Inc. Activateurs de pkc et leurs combinaisons
WO2014018563A2 (fr) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour le traitement du cancer
EP2906214A1 (fr) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Utilisation d'inhibiteurs mtor pour traiter le déficit cognitif vasculaire
WO2014063105A1 (fr) * 2012-10-19 2014-04-24 Celus Pharmaceuticals, Inc. Utilisation d'analogues de la vitamine d pour le traitement d'une affection neurologique
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN104398523B (zh) * 2014-11-03 2017-01-25 南昌大学 (22反式)‑3β‑羟基‑胆甾‑5,22‑二烯‑24‑酮在神经保护药物中的应用
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2019032685A1 (fr) * 2017-08-08 2019-02-14 Robert John Petcavich Formulations destinées à l'apport de tréhalose stimulant l'autophagie
FR3091999A1 (fr) * 2019-01-25 2020-07-31 Mexbrain Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
CN109678857B (zh) * 2019-02-12 2020-08-14 宁波大学 一种鎓溴化物以及在神经退行性疾病药物的应用

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000095A2 (fr) * 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Emploi d'inhibiteurs de calpaine dans l'inhibition et le traitement d'etats medicaux associes a une activite de calpaine accrue
WO1994002488A1 (fr) * 1992-07-24 1994-02-03 Cephalon, Inc. DERIVES DE K-252a ET DE BIS-STAUROSPORINE
JPH09221421A (ja) * 1996-02-13 1997-08-26 Kyowa Hakko Kogyo Co Ltd 抗アポトーシス剤
GB2314268A (en) * 1996-06-18 1997-12-24 Ciba Geigy Ag Pulmonary administration of desferrioxamine-B salts
WO1998002435A1 (fr) * 1996-07-12 1998-01-22 Pierre Fabre Medicament Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament
WO1998009523A1 (fr) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions et procedes de traitement de troubles neurologiques et de maladies neurodegeneratives
WO1998025887A2 (fr) * 1996-12-10 1998-06-18 Novartis Ag Formulations et formes polymorphes de desferrioxamine et rpeparation de ces dernieres
WO1998047854A1 (fr) * 1997-04-19 1998-10-29 Allergan Sales, Inc. Derives phenyles trisubstitues ayant une activite biologique de type agoniste retinoide, antagoniste, ou agoniste inverse
WO1998051702A1 (fr) * 1997-05-14 1998-11-19 Sloan-Kettering Institute For Cancer Research Methodes et compositions de destruction de proteines selectionnees
WO1999048489A2 (fr) * 1998-03-25 1999-09-30 South Alabama Medical Science Foundation Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
WO2000002836A1 (fr) * 1998-07-13 2000-01-20 Pierre Fabre Medicament Procede de preparation de derives du 2,3-dihydrobenzofurane-2,2-disubstitues
EP1006108A1 (fr) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited Dérivés de 3-hydroxy-2(1H)-pyridinone ou 3-hydroxy-4(1H)-pyridinone et utilisation comme des capteurs des espèces d'oxygène réactifs (ROS)
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
WO2001000619A1 (fr) * 1999-06-29 2001-01-04 Pierre Fabre Medicament Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique
US6187950B1 (en) * 1997-04-24 2001-02-13 Tae K. Song Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological
WO2001010829A1 (fr) * 1999-08-04 2001-02-15 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Nouveaux analogues de vitamine d
WO2001012236A2 (fr) * 1999-08-18 2001-02-22 The General Hospital Corporation Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central
WO2001051464A1 (fr) * 2000-01-10 2001-07-19 Leo Pharma A/S Nouveaux analogues de vitamine d
WO2001056982A1 (fr) * 2000-01-31 2001-08-09 Leo Pharma A/S Derives de vitamine d et leur utilisation dans le cadre du traitement de l'osteoporose et des troubles osseux associes
EP1239038A1 (fr) * 2001-03-07 2002-09-11 Galapagos Genomics B.V. Essais à haut rendement pour l'identification de modulateurs de l'activité de E2F
WO2003083067A2 (fr) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Inhibiteurs d'histone deacetylase permettant de traiter la sclerose en plaques, la sclerose laterale amyotrophique et la maladie d'alzheimer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
GB9211779D0 (en) * 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts
ES2143068T3 (es) * 1994-09-20 2000-05-01 Univ California Brefeldina a y analogos para la transmision sinaptica mejorada.
GB9521322D0 (en) * 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
US6264994B1 (en) * 1997-05-15 2001-07-24 University Of Washington Compositions for treating alzheimer's disease and other amyloidoses
WO1999037294A2 (fr) * 1998-01-26 1999-07-29 Mitokor Agents protegeant les mitochondries et utilises dans le traitement des maladies associees aux mitochondries
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
DE69903278D1 (de) * 1999-07-09 2002-11-07 Inst Pasteur De Lille Lille Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
GB0106051D0 (en) 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20050234063A1 (en) 2002-06-28 2005-10-20 Kazuhiro Terai Therapeutic agent for brain hemorrhage
GB0311835D0 (en) 2003-05-22 2003-06-25 Isis Innovation Susceptibility gene for alzheimer's disease

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000095A2 (fr) * 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Emploi d'inhibiteurs de calpaine dans l'inhibition et le traitement d'etats medicaux associes a une activite de calpaine accrue
WO1994002488A1 (fr) * 1992-07-24 1994-02-03 Cephalon, Inc. DERIVES DE K-252a ET DE BIS-STAUROSPORINE
JPH09221421A (ja) * 1996-02-13 1997-08-26 Kyowa Hakko Kogyo Co Ltd 抗アポトーシス剤
GB2314268A (en) * 1996-06-18 1997-12-24 Ciba Geigy Ag Pulmonary administration of desferrioxamine-B salts
WO1998002435A1 (fr) * 1996-07-12 1998-01-22 Pierre Fabre Medicament Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament
WO1998009523A1 (fr) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions et procedes de traitement de troubles neurologiques et de maladies neurodegeneratives
WO1998025887A2 (fr) * 1996-12-10 1998-06-18 Novartis Ag Formulations et formes polymorphes de desferrioxamine et rpeparation de ces dernieres
WO1998047854A1 (fr) * 1997-04-19 1998-10-29 Allergan Sales, Inc. Derives phenyles trisubstitues ayant une activite biologique de type agoniste retinoide, antagoniste, ou agoniste inverse
US6187950B1 (en) * 1997-04-24 2001-02-13 Tae K. Song Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological
WO1998051702A1 (fr) * 1997-05-14 1998-11-19 Sloan-Kettering Institute For Cancer Research Methodes et compositions de destruction de proteines selectionnees
WO1999048489A2 (fr) * 1998-03-25 1999-09-30 South Alabama Medical Science Foundation Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
WO2000002836A1 (fr) * 1998-07-13 2000-01-20 Pierre Fabre Medicament Procede de preparation de derives du 2,3-dihydrobenzofurane-2,2-disubstitues
EP1006108A1 (fr) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited Dérivés de 3-hydroxy-2(1H)-pyridinone ou 3-hydroxy-4(1H)-pyridinone et utilisation comme des capteurs des espèces d'oxygène réactifs (ROS)
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
WO2001000619A1 (fr) * 1999-06-29 2001-01-04 Pierre Fabre Medicament Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique
WO2001010829A1 (fr) * 1999-08-04 2001-02-15 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Nouveaux analogues de vitamine d
WO2001012236A2 (fr) * 1999-08-18 2001-02-22 The General Hospital Corporation Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central
WO2001051464A1 (fr) * 2000-01-10 2001-07-19 Leo Pharma A/S Nouveaux analogues de vitamine d
WO2001056982A1 (fr) * 2000-01-31 2001-08-09 Leo Pharma A/S Derives de vitamine d et leur utilisation dans le cadre du traitement de l'osteoporose et des troubles osseux associes
EP1239038A1 (fr) * 2001-03-07 2002-09-11 Galapagos Genomics B.V. Essais à haut rendement pour l'identification de modulateurs de l'activité de E2F
WO2003083067A2 (fr) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Inhibiteurs d'histone deacetylase permettant de traiter la sclerose en plaques, la sclerose laterale amyotrophique et la maladie d'alzheimer

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ARENDT TH ET AL: "Neuroprotection by repressing G0-G1 transition: A therapeutic strategy for AD?.", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 12, no. Supplement 11, 2000, Meeting of the Federation of European Neuroscience Societies;Brighton, UK; June 24-28, 2000, pages 522, XP001117411, ISSN: 0953-816X *
CHYAN ET AL: "neuroprotective activity of melatonin against alzheimer beta-amyloid is not mediated by melatonin receptors", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 24, no. 1/2, November 1998 (1998-11-01), pages 1455, XP002110108, ISSN: 0190-5295 *
COPANI A. ET AL: "Mitotic signaling by.beta.-amyloid causes neuronal death.", FASEB JOURNAL, vol. 13, no. 15, 1999, pages 2225 - 2234, XP001106213 *
CRAPPER MCLACHLAN D R ET AL: "INTRAMUSCULAR DESFERRIOXAMINE IN PATIENTS WITH ALZHEIMER'S DISEASE", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 337, no. 8753, 1 June 1991 (1991-06-01), pages 1304 - 1308, XP009054779, ISSN: 0140-6736 *
DATABASE WPI Week 199744, Derwent World Patents Index; AN 1997-475453, XP002433245 *
DATABASE WPI Week 200114, Derwent World Patents Index; AN 2001-127322, XP002433244 *
GIOVANNI A ET AL: "E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 275, no. 16, 21 April 2000 (2000-04-21), pages 11553 - 11560, XP002368892, ISSN: 0021-9258 *
GIOVANNI A ET AL: "Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 2 JUL 1999, vol. 274, no. 27, 2 July 1999 (1999-07-02), pages 19011 - 19016, XP002433241, ISSN: 0021-9258 *
ISRAEL C W ET AL: "DISCRIMINATION BETWEEN VENTRICULAR AND SUPRAVENTRICULAR TACHYCARDIABY DUAL CHAMBER CARDIOVERTER DEFIBRILLATORS: IMPORTANCE OF THE ATRIAL SENSING FUNCTION", PACE - PACING AND CLINICAL ELECTROPHYSIOLOGY, BLACWELL FUTURA PUBLISHING, MALDEN, MA, US, vol. 24, no. 2, 1 February 2001 (2001-02-01), pages 183 - 190, XP001006573, ISSN: 0147-8389 *
LAZAROVICI P ET AL: "K252A AND STAUROSPORINE MICROBIAL ALKALOID TOXINS AS PROTOTYPE OF NEUROTROPIC DRUGS", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 391, 1996, pages 367 - 377, XP008041521, ISSN: 0065-2598 *
NAKAI M ET AL: "PKC AND TYROSINE KINASE INVOLVEMENT IN AMYLOID BETA (25-35)-INDUCED CHEMOTAXIS OF MICROGLIA", NEUROREPORT, RAPID COMMUNICATIONS OF OXFORD, OXFORD, GB, vol. 9, no. 15, 26 October 1998 (1998-10-26), pages 3467 - 3470, XP001097833, ISSN: 0959-4965 *
NITSCH R M ET AL: "VASOPRESSIN AND BRADYKININ REGULATE SECRETORY PROCESSING OF THE AMYLOID PROTEIN PRECURSOR OF ALZHEIMER'S DISEASE", NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 23, no. 5, 1998, pages 807 - 814, XP009037707, ISSN: 0364-3190 *
PAPPOLLA ET AL: "melatonin prevents death of neuroblastoma cells exposed to the alzheimer amyloid peptide", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 17, no. 5, 1 March 1997 (1997-03-01), pages 1683 - 1690, XP002117740, ISSN: 0270-6474 *
RACCHI M ET AL: "BRADYKININ INDUCED AMYLOID PRECURSOR PROTEIN SECRETION IN FIBROBLASTS FROM ALZHEIMERS'S DISEASE, DOWN'S SYNDROME AND CONTROL DONORS", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 22, no. 1 - 3, November 1996 (1996-11-01), pages 1944, XP002052579, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
EP1769791A2 (fr) 2007-04-04
EP2289511A1 (fr) 2011-03-02
ATE535236T1 (de) 2011-12-15
ES2352964T3 (es) 2011-02-24
US8343926B2 (en) 2013-01-01
EP2286803A1 (fr) 2011-02-23
EP1764092A2 (fr) 2007-03-21
EP1764092B1 (fr) 2011-11-30
EP2292240A1 (fr) 2011-03-09
ATE524169T1 (de) 2011-09-15
ES2375293T3 (es) 2012-02-28
EP1764092A3 (fr) 2007-06-27
EP1408938A1 (fr) 2004-04-21
US8921321B2 (en) 2014-12-30
EP1769791B1 (fr) 2010-09-15
EP1767197A2 (fr) 2007-03-28
EP1767197A3 (fr) 2007-05-30
EP2286875A1 (fr) 2011-02-23
US20030032673A1 (en) 2003-02-13
GB0117645D0 (en) 2001-09-12
EP2292238A1 (fr) 2011-03-09
US20130102553A1 (en) 2013-04-25
EP1767197B1 (fr) 2011-09-14
DE60237725D1 (de) 2010-10-28
ES2373565T3 (es) 2012-02-06
ATE481093T1 (de) 2010-10-15
WO2003007925A1 (fr) 2003-01-30

Similar Documents

Publication Publication Date Title
EP1769791A3 (fr) Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
EP1392287B8 (fr) Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer.
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
PT1572095E (pt) Β-l-2'-desoxinucleósidos para tratamento de estirpes resistentes de vhb
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2002240463A1 (en) Use of endostatin in the treatment of ocular neovascularization
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2003286530A8 (en) Substituted peptides useful in the treatment of alzheimer's disease
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer
AU2003217432A1 (en) Angiopoietin-1 in the treatment of disease
AU2002348687A1 (en) Macrocycles useful in the treatment of alzheimer's disease
AU2002315098A1 (en) Macrocycles useful in the treatment of alzheimer's disease
AU2002368208A8 (en) Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1408938

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

17P Request for examination filed

Effective date: 20080111

17Q First examination report despatched

Effective date: 20080218

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: TREATMENT OF ALZHEIMER'S DISEASE WITH THE CELL CYCLE INHIBITOR DEXRAZOXANE

RTI1 Title (correction)

Free format text: USE OF DEXRAZOXANE IN THE PREVENTION AND TREATMENT OF ALZHEIMERS DISEASES

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1408938

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60237725

Country of ref document: DE

Date of ref document: 20101028

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20110214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110117

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60237725

Country of ref document: DE

Effective date: 20110616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101215

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20130730

Year of fee payment: 12

Ref country code: ES

Payment date: 20130822

Year of fee payment: 12

Ref country code: CH

Payment date: 20130726

Year of fee payment: 12

Ref country code: IE

Payment date: 20130725

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20130731

Year of fee payment: 12

Ref country code: FR

Payment date: 20130731

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130731

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60237725

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140719

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150203

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140719

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60237725

Country of ref document: DE

Effective date: 20150203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140719

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140731

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140720